Zacks Investment Research downgraded shares of DermTech (NASDAQ:KLDI) from a hold rating to a sell rating in a research note released on Tuesday, reports.

According to Zacks, “KLDiscovery Inc. provides technology-enabled services and software to law firms, corporations, government agencies and consumers solve complex data challenges. It offers data collection and forensic investigation, early case assessment, electronic discovery and data processing, application software and data hosting for web-based document reviews and managed document review services. KLDiscovery Inc., formerly known as Pivotal Acq CP, is based in McLean, United States. “

Separately, Northland Securities assumed coverage on DermTech in a research report on Monday, May 18th. They issued a buy rating and a $14.00 price objective for the company.

DermTech stock opened at $8.05 on Tuesday. The business’s fifty day moving average is $8.88. DermTech has a fifty-two week low of $4.00 and a fifty-two week high of $27.00.

About DermTech

KLDiscovery Ontrack, LLC develops e-Discovery management solutions and offers legal and technology consulting services to AmLaw 200 law firms, Fortune 500 corporations, healthcare and financial services sectors, and government agencies in the United States. Its software solutions include eDirect365, an end-to-end e-Discovery solution that helps users to find ways to cull, process, review, and manage documents; AutoRedaction that finds and redacts sensitive information from documents in a workspace; MultiMatter Management that enables organizations reuse attorney work product, spot and manage coding inconsistencies, and minimize the risk of inadvertent production of protected content across various hosted matters; and Remote Collection Manager that allows end-users and IT professionals to perform collections of hard drives, loose files, and email servers.

Featured Article: What is Depreciation?

Get a free copy of the Zacks research report on DermTech (KLDI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with's FREE daily email newsletter.